Zenabis Global Announces Q2 2019 Results

Zenabis Global (TSX:ZENA) released its financial results for the second quarter that ended on June 30, 2019.

As quoted in the press release:

Key Production Metrics

  • During the three months ended June 30, 2019, Zenabis cultivated 2,473 kg of dried cannabis, outperforming original design capacity by 35% and exceeding the Company’s 1,770 kg forecast by 40%;
  • As a result of the consistent cultivation outperformance at Zenabis Altholville, Zenabis has revised its annual production capacity estimate for Zenabis Atholville to 46,300 kg from 34,300 kg of dried cannabis, increasing Zenabis’ total licensed cultivation capacity to 54,000 kg of dried cannabis from 42,800 kg;
  • During the three months ended June 30, 2019, Zenabis’ indoor cost of cultivation was C$0.78 per gram at Zenabis Atholville; as a result, Zenabis has revised its cultivation cost estimate for Zenabis Langley from C$0.75 per gram to C$0.50 per gram.
  • Zenabis remains on track to achieve an annual cannabis cultivation capacity of 143,200 kg1 under its current capital program.

“We executed at or above plan in the second quarter and, in so doing, continued to make significant progress towards our goal of becoming one of the largest licensed producers of medical and adult-use recreational cannabis in Canada,” said Andrew Grieve, Chief Executive Officer of Zenabis.

Click here to read the full press release.

Cannabis Free Report Cover

Find out what experts say about profiting from the cannabis market in 2021!

  
Read our FREE 2021 cannabis outlook report!
 

Lexaria Appoints New Board Member

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Cannabis Weekly Round-Up: Mexico Sets Cannabis Regulations

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Cresco Labs Announces Pricing of Offering of Subordinate Voting Shares

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Ready for New Cannabis and Psychedelics Boom Ahead: CEOs of Aphria, Icanic Brands, Red Light Holland, and Tilray Discuss New Global Market Opportunities

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less